ATARA BIOTHERAPEUTICS, INC. (ATRA)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 66% below Graham Number ($14.71) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -66.3%
- Revenue declining 6% annually
ATARA BIOTHERAPEUTICS, INC. (ATRA) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $41 million . Key value metrics: P/E ratio 2.9, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ATARA BIOTHERAPEUTICS, INC. — Fundamental Analysis Summary
ATARA BIOTHERAPEUTICS, INC. (ATRA) is trading 66% below its Graham Number of $14.71 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.9x.
On financial health, ATRA shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -66.3% (sector average: -19.8%).
StockPik's composite Value Score for ATRA is 73/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ATRA shows revenue declining at 6% year-over-year, with earnings growing at 138%.